Lexeo Therapeutics (LXEO) Cash from Investing Activities (2022 - 2026)

Lexeo Therapeutics has reported Cash from Investing Activities for 5 years, with the latest figure at $27.5 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 76.03% year-over-year to $27.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$78.4 million (changed 0.14% YoY) and the FY2025 annual result came in at -$90.3 million, up 4.07% from the prior year.
• Cash from Investing Activities climbed to $27.5 million in Q1 2026 per LXEO's latest filing, from -$101.7 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $35.0 million in Q3 2025 and troughed at -$101.7 million in Q4 2025.
• A 5-year average of -$13.1 million and a median of -$95000.0 in 2022 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities slumped 128095.89% in 2024, then surged 42281.93% in 2025.
• Over 5 years, Cash from Investing Activities stood at -$107000.0 in 2022, then soared by 31.78% to -$73000.0 in 2023, then plunged by 128095.89% to -$93.6 million in 2024, then retreated by 8.66% to -$101.7 million in 2025, then surged by 127.0% to $27.5 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $27.5 million, -$101.7 million, and $35.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.